Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer: Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia.
This is a report of research efforts underway at the Arizona Cancer Center. These efforts build upon Larry Clark's unanticipated clinical prevention trial results: those results indicated that 200 microg/day of selenium in selenized yeast decreased prostate cancer risk by almost 60%. The trials underway address various phases of the possible preventive activity of selenium. The first of these, for men who are suspected to have prostate cancer but who have had a biopsy revealing no evidence of cancer, will test the ability of selenium to prevent the development of clinical prostate cancer. The second is for men with high-grade prostatic intraepithelial neoplasia; the trial will test whether selenium will prevent the development of prostatic cancer in this high-risk group. The third trial is for men who have been diagnosed with prostate cancer and are scheduled for prostatectomy: the trial is designed to test whether evidence of selenium-linked changes can be identified in the tissue removed at prostatectomy. The fourth trial is for men who have been diagnosed with prostate cancer but who have chosen neither surgery nor irradiation; this trial will evaluate whether treatment with selenium will inhibit the progress of prostate cancer. Together, these trials will provide important information as to the prostate cancer chemopreventive potential of selenium.
Clark
L C
LC
Arizona Cancer Center and Arizona College of Public Health, Tucson, Arizona 85724-5024, USA.
Marshall
J R
JR
D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001130:Arizona; D002280:Basal Cell Carcinoma / Q000517:prevention & control; D002294:Carcinoma, Squamous Cell / Q000517:prevention & control; D019587:Dietary Supplements; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D019048:Prostatic Intraepithelial Neoplasia / Q000188:drug therapy / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000097:blood / Q000517:prevention & control* / Q000601:surgery; D016032:Randomized Controlled Trials as Topic; D012645:Selenomethionine / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000517:prevention & control
D016588:Anticarcinogenic Agents; D012645:Selenomethionine; D017430:Prostate-Specific Antigen